<p>药明康德（NASDAQ:XENE - 获取免费报告）在周六发布的报告中被 StockNews.com 的股票研究分析师从 “卖出” 评级上调至 “持有” 评级。</p>
<p>获取 <strong>药明康德</strong> 的提醒：</p>
<ul>
<li>百时美施贵宝的大额收购：在两笔生物技术交易中达成 181 亿美元</li>
</ul>
<p>药明康德还受到其他几份报告的关注。加拿大皇家银行在 2 月 28 日的研究报告中重申了对药明康德股票的 “跑赢大盘” 评级。德意志银行在 2 月 11 日的研究报告中开始覆盖药明康德，设定了 “买入” 评级和 67.00 美元的目标价。HC Wainwright 在 2 月 24 日的报告中重申了 “买入” 评级，并对药明康德股票设定了 53.00 美元的目标价。最后，William Blair 在 2 月 28 日的报告中重申了对药明康德股票的 “跑赢大盘” 评级。一位股票研究分析师对该股票给予了持有评级，九位分析师则给予了买入评级。根据 MarketBeat 的数据，该股票的共识评级为 “适度买入”，共识目标价为 57.38 美元。</p>
<p><strong>查看我们关于药明康德的最新研究报告</strong></p>
<h2>药明康德的价格表现</h2>
<p>药明康德的股票在周五开盘价为 34.26 美元。该公司的市值为 26.2 亿美元，市盈率为-12.15，贝塔值为 1.26。该公司的 50 日移动平均线为 37.72 美元，200 日移动平均线为 39.73 美元。药明康德的 12 个月低点为 33.27 美元，12 个月高点为 46.00 美元。</p>
<p>药明康德（NASDAQ:XENE - 获取免费报告）最后一次公布季度财报是在 2 月 27 日，生物制药公司报告本季度每股收益为（-0.84 美元），超出市场共识预期的（-0.89 美元）0.05 美元。卖方分析师预测药明康德在当前财年的每股收益将为-3.1 美元。</p>
<h2>内部活动</h2>
<p>在相关消息中，首席执行官 Ian Mortimer 在 1 月 27 日的交易中出售了 16,315 股公司的股票。股票以平均价格 40.50 美元出售，总交易额为 660,757.50 美元。出售完成后，首席执行官现在直接持有公司 31,302 股，价值约为 1,267,731 美元。此次交易使其持股比例减少了 34.26%。该出售在向证券交易委员会提交的文件中披露，文件可通过 SEC 网站访问。公司内部人士持有公司股票的 5.52%。</p>
<h2>机构投资者对药明康德的看法</h2>
<p>一些对冲基金最近调整了对该公司的持股。摩根大通在第三季度将其在药明康德的持股增加了 1,263.2%。摩根大通现在持有 976,783 股生物制药公司的股票，价值 38,456,000 美元，此前在上个季度购买了 905,129 股。巴克莱在第三季度将其在药明康德的持股增加了 1,275.5%。巴克莱现在持有 14,993 股生物制药公司的股票，价值 590,000 美元，此前在此期间购买了 13,903 股。Walleye Capital LLC 在第三季度购买了药明康德的新头寸，价值约为 4,132,000 美元。Assenagon 资产管理公司在第四季度将其在药明康德的持股增加了 12.4%。Assenagon 资产管理公司现在持有 238,522 股生物制药公司的股票，价值 9,350,000 美元，此前在上个季度购买了 26,235 股。最后，州街公司在第三季度将其在药明康德的持股增加了 13.2%。州街公司现在持有 279,513 股生物制药公司的股票，价值 11,004,000 美元，此前在上个季度购买了 32,701 股。目前 95.45% 的股票由机构投资者和对冲基金持有。</p>
<h2>关于药明康德</h2>
<p>（获取免费报告）</p>
<p>药明康德是一家专注于神经科学的生物制药公司，致力于开发治疗加拿大神经系统疾病患者的疗法。其临床开发管道包括 XEN1101，这是一种新型且强效的 Kv7 钾通道开启剂，目前正在进行针对癫痫和其他神经系统疾病的第三阶段临床试验。</p>
<h2>精选文章</h2>
<ul>
<li>我们更看好的五只股票，而药明康德不在其中</li>
<li>低市盈率成长股：开启投资机会</li>
<li>为什么 Dollar Tree 的 Family Dollar 出售可能会引发复苏</li>
<li>道琼斯工业平均指数（DJIA）是什么？</li>
<li>摩根大通：银行业的 “NVIDIA”，准备迎接更多收益？</li>
<li>纳斯达克股票交易所是什么？</li>
<li>购买 Chewy 股票反转？现在是时候了</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9WEVORQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9WEVORQ"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对该故事有任何问题或意见，请发送电子邮件至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在药明康德吗？</h2>
<p>在考虑药明康德之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐在更广泛的市场注意到之前购买，而药明康德不在名单上。</p>
<p>虽然药明康德目前在分析师中获得了买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

Xenon制药

<p>StockNews.com 在最近的一份报告中将 Xenon Pharmaceuticals (NASDAQ:XENE) 的评级从 “卖出” 上调至 “持有”。其他分析师也给予了积极的评级，其中一位维持了 “跑赢大盘” 的评级，其他分析师则将目标价设定在 $53.00 到 $67.00 之间。该股票开盘价为 $34.26，市值为 $26.2 亿。内部交易活动包括首席执行官 Ian Mortimer 出售股份，减少了他的持股比例。机构投资者持有该股票的 95.45%，显示出机构对这家专注于开发神经系统疾病治疗的公司的强烈兴趣</p>

<p>Xenon Pharmaceuticals (NASDAQ:XENE - Get Free Report) was upgraded by equities research analysts at StockNews.com from a &#34;sell&#34; rating to a &#34;hold&#34; rating in a report issued on Saturday.</p>
<div class="lb-trans"><p>药明康德（NASDAQ:XENE - 获取免费报告）在周六发布的报告中被 StockNews.com 的股票研究分析师从 “卖出” 评级上调至 “持有” 评级。</p>
</div><p>Get <strong>Xenon Pharmaceuticals</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>药明康德</strong> 的提醒：</p>
</div><ul>
<li>Bristol Myers Squibb’s big buys: $18.1 billion in 2 biotech deals</li>
</ul>
<div class="lb-trans"><ul>
<li>百时美施贵宝的大额收购：在两笔生物技术交易中达成 181 亿美元</li>
</ul>
</div><p>XENE has been the subject of several other reports. Royal Bank of Canada reissued an &#34;outperform&#34; rating on shares of Xenon Pharmaceuticals in a research report on Friday, February 28th. Deutsche Bank Aktiengesellschaft assumed coverage on Xenon Pharmaceuticals in a research report on Tuesday, February 11th. They set a &#34;buy&#34; rating and a $67.00 price target for the company. HC Wainwright reaffirmed a &#34;buy&#34; rating and issued a $53.00 price objective on shares of Xenon Pharmaceuticals in a report on Monday, February 24th. Finally, William Blair reaffirmed an &#34;outperform&#34; rating on shares of Xenon Pharmaceuticals in a report on Friday, February 28th. One equities research analyst has rated the stock with a hold rating and nine have assigned a buy rating to the company's stock. According to data from MarketBeat, the stock has a consensus rating of &#34;Moderate Buy&#34; and a consensus price target of $57.38.</p>
<div class="lb-trans"><p>药明康德还受到其他几份报告的关注。加拿大皇家银行在 2 月 28 日的研究报告中重申了对药明康德股票的 “跑赢大盘” 评级。德意志银行在 2 月 11 日的研究报告中开始覆盖药明康德，设定了 “买入” 评级和 67.00 美元的目标价。HC Wainwright 在 2 月 24 日的报告中重申了 “买入” 评级，并对药明康德股票设定了 53.00 美元的目标价。最后，William Blair 在 2 月 28 日的报告中重申了对药明康德股票的 “跑赢大盘” 评级。一位股票研究分析师对该股票给予了持有评级，九位分析师则给予了买入评级。根据 MarketBeat 的数据，该股票的共识评级为 “适度买入”，共识目标价为 57.38 美元。</p>
</div><p><strong>Check Out Our Latest Research Report on Xenon Pharmaceuticals</strong></p>
<div class="lb-trans"><p><strong>查看我们关于药明康德的最新研究报告</strong></p>
</div><h2>Xenon Pharmaceuticals Price Performance</h2>
<div class="lb-trans"><h2>药明康德的价格表现</h2>
</div><p>XENE stock opened at $34.26 on Friday. The company has a market capitalization of $2.62 billion, a PE ratio of -12.15 and a beta of 1.26. The firm's 50-day moving average is $37.72 and its 200 day moving average is $39.73. Xenon Pharmaceuticals has a 12 month low of $33.27 and a 12 month high of $46.00.</p>
<div class="lb-trans"><p>药明康德的股票在周五开盘价为 34.26 美元。该公司的市值为 26.2 亿美元，市盈率为-12.15，贝塔值为 1.26。该公司的 50 日移动平均线为 37.72 美元，200 日移动平均线为 39.73 美元。药明康德的 12 个月低点为 33.27 美元，12 个月高点为 46.00 美元。</p>
</div><p>Xenon Pharmaceuticals (NASDAQ:XENE - Get Free Report) last announced its quarterly earnings results on Thursday, February 27th. The biopharmaceutical company reported ($0.84) EPS for the quarter, beating the consensus estimate of ($0.89) by $0.05. Sell-side analysts forecast that Xenon Pharmaceuticals will post -3.1 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>药明康德（NASDAQ:XENE - 获取免费报告）最后一次公布季度财报是在 2 月 27 日，生物制药公司报告本季度每股收益为（-0.84 美元），超出市场共识预期的（-0.89 美元）0.05 美元。卖方分析师预测药明康德在当前财年的每股收益将为-3.1 美元。</p>
</div><h2>Insider Activity</h2>
<div class="lb-trans"><h2>内部活动</h2>
</div><p>In related news, CEO Ian Mortimer sold 16,315 shares of the business's stock in a transaction that occurred on Monday, January 27th. The stock was sold at an average price of $40.50, for a total transaction of $660,757.50. Following the completion of the sale, the chief executive officer now directly owns 31,302 shares in the company, valued at approximately $1,267,731. The trade was a 34.26 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities &amp; Exchange Commission, which can be accessed through the SEC website. Company insiders own 5.52% of the company's stock.</p>
<div class="lb-trans"><p>在相关消息中，首席执行官 Ian Mortimer 在 1 月 27 日的交易中出售了 16,315 股公司的股票。股票以平均价格 40.50 美元出售，总交易额为 660,757.50 美元。出售完成后，首席执行官现在直接持有公司 31,302 股，价值约为 1,267,731 美元。此次交易使其持股比例减少了 34.26%。该出售在向证券交易委员会提交的文件中披露，文件可通过 SEC 网站访问。公司内部人士持有公司股票的 5.52%。</p>
</div><h2>Institutional Investors Weigh In On Xenon Pharmaceuticals</h2>
<div class="lb-trans"><h2>机构投资者对药明康德的看法</h2>
</div><p>A number of hedge funds have recently modified their holdings of the business. JPMorgan Chase &amp; Co. grew its position in shares of Xenon Pharmaceuticals by 1,263.2% in the third quarter. JPMorgan Chase &amp; Co. now owns 976,783 shares of the biopharmaceutical company's stock valued at $38,456,000 after purchasing an additional 905,129 shares in the last quarter. Barclays PLC increased its stake in Xenon Pharmaceuticals by 1,275.5% during the third quarter. Barclays PLC now owns 14,993 shares of the biopharmaceutical company's stock worth $590,000 after purchasing an additional 13,903 shares during the period. Walleye Capital LLC purchased a new position in Xenon Pharmaceuticals in the 3rd quarter valued at approximately $4,132,000. Assenagon Asset Management S.A. grew its stake in Xenon Pharmaceuticals by 12.4% during the 4th quarter. Assenagon Asset Management S.A. now owns 238,522 shares of the biopharmaceutical company's stock worth $9,350,000 after purchasing an additional 26,235 shares in the last quarter. Finally, State Street Corp grew its position in shares of Xenon Pharmaceuticals by 13.2% during the third quarter. State Street Corp now owns 279,513 shares of the biopharmaceutical company's stock worth $11,004,000 after buying an additional 32,701 shares in the last quarter. 95.45% of the stock is currently owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>一些对冲基金最近调整了对该公司的持股。摩根大通在第三季度将其在药明康德的持股增加了 1,263.2%。摩根大通现在持有 976,783 股生物制药公司的股票，价值 38,456,000 美元，此前在上个季度购买了 905,129 股。巴克莱在第三季度将其在药明康德的持股增加了 1,275.5%。巴克莱现在持有 14,993 股生物制药公司的股票，价值 590,000 美元，此前在此期间购买了 13,903 股。Walleye Capital LLC 在第三季度购买了药明康德的新头寸，价值约为 4,132,000 美元。Assenagon 资产管理公司在第四季度将其在药明康德的持股增加了 12.4%。Assenagon 资产管理公司现在持有 238,522 股生物制药公司的股票，价值 9,350,000 美元，此前在上个季度购买了 26,235 股。最后，州街公司在第三季度将其在药明康德的持股增加了 13.2%。州街公司现在持有 279,513 股生物制药公司的股票，价值 11,004,000 美元，此前在上个季度购买了 32,701 股。目前 95.45% 的股票由机构投资者和对冲基金持有。</p>
</div><h2>About Xenon Pharmaceuticals</h2>
<div class="lb-trans"><h2>关于药明康德</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Xenon Pharmaceuticals Inc, a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders.</p>
<div class="lb-trans"><p>药明康德是一家专注于神经科学的生物制药公司，致力于开发治疗加拿大神经系统疾病患者的疗法。其临床开发管道包括 XEN1101，这是一种新型且强效的 Kv7 钾通道开启剂，目前正在进行针对癫痫和其他神经系统疾病的第三阶段临床试验。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>精选文章</h2>
</div><ul>
<li>Five stocks we like better than Xenon Pharmaceuticals</li>
<li>Low PE Growth Stocks: Unlocking Investment Opportunities</li>
<li>Why Dollar Tree’s Family Dollar Sale Could Spark a Comeback</li>
<li>What is the Dow Jones Industrial Average (DJIA)?</li>
<li>JPMorgan: The 'NVIDIA of Banking' Poised for More Gains?</li>
<li>What is the NASDAQ Stock Exchange?</li>
<li>Buy the Chewy Stock Reversal? Here’s Why Now Is the Time</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，而药明康德不在其中</li>
<li>低市盈率成长股：开启投资机会</li>
<li>为什么 Dollar Tree 的 Family Dollar 出售可能会引发复苏</li>
<li>道琼斯工业平均指数（DJIA）是什么？</li>
<li>摩根大通：银行业的 “NVIDIA”，准备迎接更多收益？</li>
<li>纳斯达克股票交易所是什么？</li>
<li>购买 Chewy 股票反转？现在是时候了</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9WEVORQ" alt="" original-src="https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NASDAQ&amp;Symbol=XENE"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对该故事有任何问题或意见，请发送电子邮件至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Xenon Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在药明康德吗？</h2>
</div><p>Before you consider Xenon Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑药明康德之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Xenon Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐在更广泛的市场注意到之前购买，而药明康德不在名单上。</p>
</div><p>While Xenon Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然药明康德目前在分析师中获得了买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

StockNews.com 将 Xenon 制药（NASDAQ:XENE）的评级上调至持有